US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

RedCloud Holdings plc

1.62

-0.0300-1.82%

Volume:25.71K

Turnover:41.90K

Market Cap:71.65M

PE:-0.78

High:1.70

Open:1.65

Low:1.58

Close:1.65

Loading ...

Overview Company News Filings

RedCloud Launches Red101 Agentic AI and new actionable market insights, advancing supply chain accessibility for global and local trade

Catheter Precision, Inc. Announces Fourth Quarter and Full Year 2024 Update and Financial Results

RedCloud Raises $20 Million in IPO

MT Newswires Live

Redcloud Holdings Announces Closing of $20 Million Initial Public Offering

THOMSON REUTERS

RedCloud Prices $20 Million IPO

MT Newswires Live

Redcloud Holdings Announces Pricing of $20 Million Initial Public Offering

THOMSON REUTERS

RedCloud Holdings Announces Pricing of $20 Million Initial Public Offering

MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22

Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis

AngioDynamics Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb Ischemia

Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

RedCloud Files for IPO of 11 Million Shares

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RCT/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RCT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RCT\",,,,,undefined,":{"symbol":"RCT","market":"US","secType":"STK","nameCN":"RedCloud Holdings plc","latestPrice":1.62,"timestamp":1750104000000,"preClose":1.65,"halted":0,"volume":25707,"delay":0,"floatShares":6704041,"shares":44226635,"eps":-2.087317,"marketStatus":"Post-Mkt","change":-0.03,"latestTime":"06-16 18:32:03 EDT","open":1.65,"high":1.6998,"low":1.58,"amount":41895.6747,"amplitude":0.072606,"askPrice":1.69,"askSize":588,"bidPrice":1.55,"bidSize":507,"shortable":0,"etf":0,"ttmEps":-2.087317,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1750118400000},"marketStatusCode":4,"adr":0,"listingDate":1742529600000,"exchange":"NASDAQ","adjPreClose":1.65,"preHourTrading":{"tag":"盘前","latestPrice":1.6995,"preClose":1.65,"latestTime":"09:22 EDT","volume":77,"amount":127.80749519999999,"timestamp":1750080124003},"volumeRatio":0.895409},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RCT\",,,,,undefined,":{"symbol":"RCT","floatShares":6704041,"roa":"-194.04%","roe":"--","lyrEps":-2.087317,"volumeRatio":0.895409,"shares":44226635,"dividePrice":0,"high":1.6998,"amplitude":0.072606,"preClose":1.65,"low":1.58,"week52Low":1.23,"pbRate":"-1.04","psRate":"1.54","week52High":5,"institutionHeld":0,"latestPrice":1.62,"committee":-0.073973,"eps":-2.087317,"divideRate":0,"volume":25707,"delay":0,"ttmEps":-2.087317,"open":1.65,"prevYearClose":4.5,"prevWeekClose":1.65,"prevMonthClose":1.73,"prevQuarterClose":2.14,"fiveDayClose":1.63,"twentyDayClose":1.609,"sixtyDayClose":4.5},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RCT\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526565061","title":"RedCloud Launches Red101 Agentic AI and new actionable market insights, advancing supply chain accessibility for global and local trade","url":"https://stock-news.laohu8.com/highlight/detail?id=2526565061","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526565061?lang=en_us&edition=fundamental","pubTime":"2025-04-10 20:00","pubTimestamp":1744286400,"startTime":"0","endTime":"0","summary":"LONDON, April 10, 2025  -- Trading platform company RedCloud Holdings plc  has announced the launch of its innovative Red101 agentic AI technology providing intuitive trading intelligence to its platform in fast growth commerce markets. This and two new insight-based tools described below are designed to empower brands, distributors, and retailers in emerging markets - leveraging AI-driven insights and recommendations - to enable business decision making for growth and profitability.RedInsights Retail Opportunity Maps: Available today, these interactive maps allow brands, distributors, and wholesalers to visually identify untapped growth opportunities. By displaying product penetration and customer coverage across urban areas, businesses can take immediate action to maximize their retail coverage and market share.The launch of these tools underscores RedCloud’s commitment to challenging inefficient legacy systems that dominate global commerce. By introducing disruptive solutions, the c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/redcloud-launches-red101-agentic-ai-120000033.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RCT"],"gpt_icon":0},{"id":"2522081573","title":"Catheter Precision, Inc.  Announces Fourth Quarter and Full Year 2024 Update and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2522081573","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522081573?lang=en_us&edition=fundamental","pubTime":"2025-03-28 20:00","pubTimestamp":1743163200,"startTime":"0","endTime":"0","summary":"FORT MILL, S.C., March 28, 2025  --  Catheter Precision, Inc. , a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending December 31, 2024.Highlights of 2024 and the fourth quarter include:. New Chief Commercial Officer  joined in Q2, 2024.Replaced the majority of our prior sales team with new salespeople selected by our new CCO and our CEO. Training was completed in Q3, 2024.The first sales of LockeT occurred in Q2 2024 and grew sequentially each quarter through the end of the year, to both new and repeat customers.VIVO marketing and sales progress continues in both the US and multiple international markets including Germany, Turkey, Portugal, France, Switzerland, UK, Italy, Sweden, Brunei, and Qatar. Abstract at the American College of Cardiology meeting titled Feasibility, Safety, and Efficacy of a Novel External Compression Vascular Closure Device: The LockeT Study . Rand","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/catheter-precision-inc-announces-fourth-120000300.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CCO","BK4585","LU2357125470.USD","BK4588","RCT","LU2294711713.HKD","VTAK","LU0823414551.USD","LU0823414478.USD","VT","LU2506951792.HKD","BK4082","BK4009","LU2249611893.SGD"],"gpt_icon":0},{"id":"2522108536","title":"RedCloud Raises $20 Million in IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2522108536","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522108536?lang=en_us&edition=fundamental","pubTime":"2025-03-25 05:27","pubTimestamp":1742851677,"startTime":"0","endTime":"0","summary":"RedCloud Holdings  said Monday it closed its $20 million initial public offering, selling 4.4 million shares at $4.50 per share.Underwriters have a 30-day option to buy up to an additional 666,666 shares, according to RedCloud.The company's shares started trading on the Nasdaq on Friday and closed 6.2% higher Monday at $4.78.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RCT","BK7078","NQmain","RCT.AU"],"gpt_icon":0},{"id":"2522707470","title":"Redcloud Holdings Announces Closing of $20 Million Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2522707470","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522707470?lang=en_us&edition=fundamental","pubTime":"2025-03-25 04:15","pubTimestamp":1742847300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nTUA3MMLRK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCT"],"gpt_icon":0},{"id":"2521798564","title":"RedCloud Prices $20 Million IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2521798564","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521798564?lang=en_us&edition=fundamental","pubTime":"2025-03-21 16:45","pubTimestamp":1742546704,"startTime":"0","endTime":"0","summary":"RedCloud Holdings said Thursday it priced its initial public offering of about 4.4 million ordinary shares at $4.50 per share, for expected gross proceeds of $20 million.IPO underwriters have a 30-day option to buy up to an additional 666,666 shares. The offering is expected to close Monday.The shares are expected to start trading on the Nasdaq Capital Market under the ticker symbol \"RCT\" Friday.The RedCloud platform facilities the trading of supplies of fast-moving consumer goods products across business supply chains, the company said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RCT"],"gpt_icon":0},{"id":"2521905994","title":"Redcloud Holdings Announces Pricing  of $20 Million Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2521905994","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521905994?lang=en_us&edition=fundamental","pubTime":"2025-03-21 06:25","pubTimestamp":1742509500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nTUABRRXDV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCT"],"gpt_icon":0},{"id":"2521490790","title":"RedCloud Holdings Announces Pricing  of $20 Million Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2521490790","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521490790?lang=en_us&edition=fundamental","pubTime":"2025-03-21 06:25","pubTimestamp":1742509500,"startTime":"0","endTime":"0","summary":"LONDON, March 20, 2025  -- RedCloud Holdings plc , today announced the pricing of its initial public offering of 4,444,445 of its ordinary shares at a public offering price of $4.50 per share . RedCloud has granted the underwriters a 30-day option to purchase up to an additional 666,666 ordinary shares from RedCloud to cover over-allotments in connection with the Offering. The gross proceeds of the Offering are expected to be approximately $20 million before deducting underwriting discounts and offering expenses, assuming no exercise of the over-allotment option. The Offering is expected to close on March 24, 2025, subject to the satisfaction of customary closing conditions.The ordinary shares are expected to begin trading on the Nasdaq Capital Market under the ticker symbol “RCT” on March 21, 2025.This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/redcloud-holdings-announces-pricing-20-222500087.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RCT"],"gpt_icon":0},{"id":"2518224329","title":"MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22","url":"https://stock-news.laohu8.com/highlight/detail?id=2518224329","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518224329?lang=en_us&edition=fundamental","pubTime":"2025-03-10 18:05","pubTimestamp":1741601100,"startTime":"0","endTime":"0","summary":"Five presentations affirm positive outcomes utilizing inhaled insulinAn sNDA filing for Afrezza in pediatric population anticipated in 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March  10, 2025   -- MannKind Corporation , a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, will showcase data from recent studies of inhaled insulin across five presentations at the 18th International Conference on Advanced Technologies and Treatments for Diabetes to be held March 19-22 in Amsterdam. “Data from both the INHALE-1 pediatric and INHALE-3 adult studies continue to drive groundbreaking conversations around inhaled insulin,” said Dr. Kevin Kaiserman, Senior Vice President, Therapeutic Area Head, Endocrine Diseases for MannKind Corporation. \"Afrezza continues to be an important treatment option for adults living with diabetes, including those utilizing MDI and AID, and we look ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/10/3039535/29517/en/MannKind-Showcases-Efficacy-Safety-and-Mealtime-Control-Data-from-Recent-Pediatric-and-Adult-Studies-of-Afrezza-at-the-ATTD-Conference-March-19-22.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAA","BK4584","MNKD","RCT","CET","BK4139"],"gpt_icon":0},{"id":"2517441022","title":"Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2517441022","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517441022?lang=en_us&edition=fundamental","pubTime":"2025-03-08 22:00","pubTimestamp":1741442400,"startTime":"0","endTime":"0","summary":"Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm. Nearly half of patients with moderate-to-severe plaque psoriasis  treated with investigational icotrokinra achieved completely clear skin  at Week 24 in Phase 3 ICONIC-LEAD. Topline results from Phase 3 ICONIC-ADVANCE 1&2studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO. Data from the Phase 3 ICONIC-LEADa study, presented as a late-breaking abstract at the 2025 American Academy of Dermatology  Annual Meeting, show once daily icotrokinra demonstrated significant skin clearance and a favorable safety profile in adults and adolescents 12 years of age and older with moderate-to-severe plaque PsO.1. \"People living with moderate-to-severe plaque psoriasis are seeking options that balance efficacy, safety and ease of use,\" said Robert Bissonnette, M.D., Chairman at Innovaderm Research, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/icotrokinra-results-show-potential-set-140000829.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/icotrokinra-results-show-potential-set-140000829.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RCT","SG9999001440.SGD","LU0114720955.EUR","LU0345769631.USD","LU0203345920.USD","LU1244550577.SGD","LU1894683348.USD","LU1221951046.USD","LU0889566641.SGD","LU1732799900.SGD","LU1506573853.SGD","BK4588","LU1066051225.USD","LU1585245621.USD","LU1066051811.HKD","IGA","LU0203347892.USD","IE000M9KFDE8.USD","LU0234570918.USD","IE00B19Z3B42.SGD","LU2112291526.USD","IE0002270589.USD","LU0882574055.USD","LU1023059063.AUD","LU2089984988.USD","JNJ","LU2468319806.SGD","LU0912757837.SGD","IE00BSNM7G36.USD","BK4581","BK4585","LU1778281490.HKD","LU0795875169.SGD","LU0345770993.USD","LU1261432733.SGD","BK4534","LU0640476718.USD","BK4533","IE00B19Z3581.USD","LU1162221912.USD","LU1074936037.SGD","BK4568","LU1280957306.USD","BK4550","BK4559","LU0122379950.USD","IE00B1BXHZ80.USD","LU2602419157.SGD","IE00BDGV0183.EUR"],"gpt_icon":0},{"id":"2507164777","title":"AngioDynamics Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb Ischemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2507164777","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507164777?lang=en_us&edition=fundamental","pubTime":"2025-01-30 20:30","pubTimestamp":1738240200,"startTime":"0","endTime":"0","summary":"Trial Evaluates Effectiveness of Innovative Auryon Atherectomy System in Complex Below-the-Knee Cases. AMBITION BTK is a multicenter, randomized controlled trial  designed to evaluate the clinical outcomes of the Auryon Atherectomy System in combination with standard balloon angioplasty compared to standard balloon angioplasty alone for the treatment of infrapopliteal lesions in patients with critical limb ischemia. The trial will enroll up to 200 subjects across up to 30 hospital-based sites. Additionally, up to 1,500 subjects treated with the Auryon Atherectomy System at the same sites who do not meet the eligibility criteria of the RCT will be enrolled in a companion Registry.\"With the global rise in diabetes, we are seeing a growing number of patients with severe tibial disease,\" said AMBITION BTK Co-Principal Investigator Anahita Dua, MD, MS, MBA, FACS, vascular surgeon at Massachusetts General Hospital and an associate professor of Surgery at Harvard Medical School. \"In the Unite","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/angiodynamics-initiates-ambition-btk-rct-123000249.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LEA","BK4124","RCT","BK4082","ANGO"],"gpt_icon":0},{"id":"2507763614","title":"Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2507763614","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507763614?lang=en_us&edition=fundamental","pubTime":"2025-01-29 22:00","pubTimestamp":1738159200,"startTime":"0","endTime":"0","summary":"Completion enables the End-of-Phase 2 (EOP2) interaction with the FDA on the design of the Phase 3 program and is expected to facilitate ongoing partnership discussions Adial’s formulation exhibited p","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/29/3017232/26135/en/Adial-Pharmaceuticals-Announces-Positive-Clinical-Study-Results-from-the-AD04-103-Pharmacokinetics-Study-of-AD04-for-the-Treatment-of-Alcohol-Use-Disorder.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4125","RCT","BK4007","PK","LU2238339852.HKD","BK4181","LU1043141123.HKD","ADIL","AUD","LU0426417589.USD","BK4218","LU0426412945.USD","LU0345774631.USD","LU0994945656.USD"],"gpt_icon":0},{"id":"2505084712","title":"RedCloud Files for IPO of 11 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2505084712","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505084712?lang=en_us&edition=fundamental","pubTime":"2025-01-21 23:59","pubTimestamp":1737475162,"startTime":"0","endTime":"0","summary":"RedCloud said Tuesday it launched a proposed initial public offering of 11 million shares, with the IPO price currently expected at between $4 and $6 per share.Underwriters will be granted a 30-day option to purchase up to 1.7 million additional shares, the company said.The company said it plans to list its shares on the Nasdaq Capital Market under the \"RCT\" ticker symbol.Net proceeds from the offering will be used for AI capabilities' development, platform upgrade investments, to repay debts, and for working capital and general purposes, according to the company.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RCT"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":32,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RCT\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RCT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RCT\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RCT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RCT","date":"2025-06-13","current":-1.421442,"percent":0.933333,"low":-8.372888,"twenty":-5.286393,"median":-1.780563,"eighty":-1.504078,"high":-1.377839,"avg":-2.971738,"sd":2.180896,"marketCap":72089415},"quantilePoints":[{"date":"2025-02-07","current":-8.372888,"twenty":-8.372888,"median":-8.372888,"eighty":-8.372888,"marketCap":334832545},{"date":"2025-02-12","current":-8.372888,"twenty":-8.372888,"median":-8.372888,"eighty":-8.372888,"marketCap":334832545},{"date":"2025-03-07","current":-5.31765,"twenty":-8.372888,"median":-8.372888,"eighty":-8.372888,"marketCap":212653295},{"date":"2025-03-14","current":-5.31765,"twenty":-8.372888,"median":-8.372888,"eighty":-5.31765,"marketCap":212653295},{"date":"2025-03-21","current":-4.976729,"twenty":-8.372888,"median":-5.31765,"eighty":-5.31765,"marketCap":199019857},{"date":"2025-03-28","current":-2.665315,"twenty":-8.372888,"median":-5.31765,"eighty":-4.790886,"marketCap":106586190},{"date":"2025-04-04","current":-1.636902,"twenty":-8.372888,"median":-5.31765,"eighty":-3.23598,"marketCap":65459842},{"date":"2025-04-11","current":-1.559375,"twenty":-7.150793,"median":-4.976729,"eighty":-1.747385,"marketCap":62359555},{"date":"2025-04-17","current":-1.979632,"twenty":-5.31765,"median":-4.790886,"eighty":-1.747385,"marketCap":79165676},{"date":"2025-04-25","current":-1.857979,"twenty":-5.31765,"median":-4.202571,"eighty":-1.769504,"marketCap":74300746},{"date":"2025-05-02","current":-1.780563,"twenty":-5.31765,"median":-2.366711,"eighty":-1.747385,"marketCap":71204882},{"date":"2025-05-09","current":-1.669969,"twenty":-5.31765,"median":-2.040128,"eighty":-1.687665,"marketCap":66782218},{"date":"2025-05-16","current":-1.403129,"twenty":-5.31765,"median":-2.001751,"eighty":-1.687665,"marketCap":71160655},{"date":"2025-05-23","current":-1.534808,"twenty":-5.31765,"median":-1.974102,"eighty":-1.661122,"marketCap":77838877},{"date":"2025-05-30","current":-1.526088,"twenty":-5.31765,"median":-1.896687,"eighty":-1.604572,"marketCap":77396611},{"date":"2025-06-06","current":-1.482485,"twenty":-5.31765,"median":-1.857979,"eighty":-1.534808,"marketCap":75185279},{"date":"2025-06-13","current":-1.421442,"twenty":-5.286393,"median":-1.780563,"eighty":-1.504078,"marketCap":72089415}],"updateTime":1750113123876}}}